The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
- Published in:
- Oncology, 2023, v. 101, n. 12, p. 836, doi. 10.1159/000533866
- By:
- Publication type:
- Article
Works matching AU Jørgensen, Jan Trøst
Results: 30
1
2
Companion Diagnostics in Oncology - Current Status and Future Aspects.
- Published in:
- Oncology, 2013, v. 85, n. 1, p. 59, doi. 10.1159/000353454
- By:
- Publication type:
- Article
3
Targeted HER2 Treatment in Advanced Gastric Cancer.
- Published in:
- Oncology, 2010, v. 78, n. 1, p. 26, doi. 10.1159/000288295
- By:
- Publication type:
- Article
4
Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.
- Published in:
- Oncologist, 2019, v. 24, n. 7, p. e432, doi. 10.1634/theoncologist.2019-0054
- By:
- Publication type:
- Article
5
New Era of Personalized Medicine: A 10-Year Anniversary.
- Published in:
- 2009
- By:
- Publication type:
- Letter
6
Pharmacodiagnostics and Targeted Therapies--A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer.
- Published in:
- Oncologist, 2007, v. 12, n. 4, p. 397, doi. 10.1634/theoncologist.12-4-397
- By:
- Publication type:
- Article
7
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.676939
- By:
- Publication type:
- Article
8
Drug-Diagnostic Co-Development in Cancer.
- Published in:
- Pharmaceutical Medicine, 2010, v. 24, n. 6, p. 363, doi. 10.1007/BF03256837
- By:
- Publication type:
- Article
9
The impact of companion diagnostic testing on medical decision making and IVD regulations.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
10
Predictive biomarkers and personalized pharmacotherapy.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
11
An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
- Published in:
- Expert Review of Molecular Diagnostics, 2021, v. 21, n. 5, p. 445, doi. 10.1080/14737159.2021.1920396
- By:
- Publication type:
- Article
12
Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
- Published in:
- Expert Review of Molecular Diagnostics, 2020, v. 20, n. 6, p. 557, doi. 10.1080/14737159.2020.1762573
- By:
- Publication type:
- Article
13
Site-agnostic biomarker-guided oncology drug development.
- Published in:
- Expert Review of Molecular Diagnostics, 2020, v. 20, n. 6, p. 583, doi. 10.1080/14737159.2020.1702521
- By:
- Publication type:
- Article
14
When biomarkers define a drug indication.
- Published in:
- Expert Review of Molecular Diagnostics, 2018, v. 18, n. 4, p. 315, doi. 10.1080/14737159.2018.1428090
- By:
- Publication type:
- Article
15
Companion Diagnostics and the Drug-Diagnostic Codevelopment Model.
- Published in:
- Drug Development Research, 2012, v. 73, n. 7, p. 390, doi. 10.1002/ddr.21029
- By:
- Publication type:
- Article
16
Predictive biomarkers and clinical evidence.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2021, v. 128, n. 5, p. 642, doi. 10.1111/bcpt.13578
- By:
- Publication type:
- Article
17
Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00105
- By:
- Publication type:
- Article
18
Companion Diagnostics for Targeted Cancer Drugs - Clinical and Regulatory Aspects.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00105
- By:
- Publication type:
- Article
19
The Different Roles of MET in the Development and Treatment of Cancer.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
20
Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC.
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092150
- By:
- Publication type:
- Article
21
Are We Making personalized Cancer Care Less personalized?
- Published in:
- 2016
- By:
- Publication type:
- Opinion
22
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
- Published in:
- Acta Oncologica, 2008, v. 47, n. 6, p. 1054, doi. 10.1080/02841860801942158
- By:
- Publication type:
- Article
23
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
- Published in:
- Acta Oncologica, 2008, v. 47, n. 4, p. 725, doi. 10.1080/02841860801995396
- By:
- Publication type:
- Article
24
Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 6, p. 999, doi. 10.1002/cpt.955
- By:
- Publication type:
- Article
25
High Concordance Between Two Companion Diagnostics Tests.
- Published in:
- American Journal of Clinical Pathology, 2011, v. 136, n. 1, p. 145, doi. 10.1309/AJCPJPJ8ZWGDTTWC
- By:
- Publication type:
- Article
26
The importance of predictive biomarkers in oncology drug development.
- Published in:
- Expert Review of Molecular Diagnostics, 2016, v. 16, n. 8, p. 807, doi. 10.1080/14737159.2016.1199962
- By:
- Publication type:
- Article
27
Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
28
Companion diagnostics: the key to personalized medicine.
- Published in:
- Expert Review of Molecular Diagnostics, 2015, v. 15, n. 2, p. 153, doi. 10.1586/14737159.2015.1002470
- By:
- Publication type:
- Article
29
A changing landscape for companion diagnostics.
- Published in:
- Expert Review of Molecular Diagnostics, 2013, v. 13, n. 7, p. 667, doi. 10.1586/14737159.2013.834799
- By:
- Publication type:
- Article
30
Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development.
- Published in:
- Expert Review of Molecular Diagnostics, 2008, v. 8, n. 6, p. 689, doi. 10.1586/14737159.8.6.689
- By:
- Publication type:
- Article